Preclinically, transgenic mice with EL-4 thymoma or B16-F10 melanoma xenografts grown in mice with T cells deficient in TGFβ signalling generate tumour-specific CTLs that eradicate tumours [165]. This evidence concerns the gene TGFB1 and neoplasm.